Testing is one piece of reopening, but experts are still relying on the help of a vaccine to keep the public safe. Researchers are increasingly optimistic that scientists are getting closer to development even though we’re barely months into identifying and learning about the novel strain of SARS. Human and clinical trials are well underway, but just when they’ll be ready for manufacturing and distribution is another story. What is a realistic timeline and does one exist? We asked Dr. Vincent Silenzio an expert in urban and global public health at Rutgers University. To read the full story.
Recent Posts
- Founding partner Microsoft to bring new Discovery AI technology to NJ AI Hub.
- In Once-Redlined City Neighborhoods, Ambulances Still Lag Behind.
- How Alcohol Ads in Your Feed May Lead to Alcohol in Your Glass.
- Launch of NJIT’s B.S. in Enterprise AI Cultivates Next-Generation Tech Talent.
- Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers.
Categories
- Community (2,401)
- Covid (993)
- CTO Events (6)
- News (3,039)
- Pilots (21)